BillionToOne CEO sells shares in trading plan

Posted by Francis Steltz on Oct 2nd, 2026

What happened

BillionToOne, Inc. (NASDAQ: BLLN) said Chairman and CEO Oguzhan Atay, a director, sold 10,999 shares on 2026-09-28. The shares changed hands at $120.64 each, for about $1.33 million. The filing says the trade was made under a Rule 10b5-1 trading plan.

It also says Atay held 154,502 shares after the sale. The filing marks the trade in a Form 4 report and ties it to the Rule 10b5-1 plan. Investors can read it as a routine insider update for the stock. That is the near-term takeaway.

Key numbers

Metric	Latest	Source
Shares sold	10,999 shares	SEC Form 4
Sale price	$120.64 per share	SEC Form 4
Reported value	about $1.33 million	SEC Form 4
Shares held after sale	154,502 shares	SEC Form 4

Read more: BillionToOne (BLLN) stock analysis and investment case

Why it matters

OptimistFi's case is that BillionToOne works if its prenatal and oncology molecular tests stay differentiated enough to keep winning orders and reimbursement while lab scale turns that volume into durable cash generation. This filing is mixed for that case because it shows the CEO reducing exposure under a preset sale while the stock still sits inside the long-term operating story. That is why it reads as a mixed signal rather than a fundamental update.

The 10,999 shares were about 6.6% of the holding before the trade, so the sale looks like a partial trim rather than a full exit. That makes the disclosure mixed for investors: it shows the CEO reducing exposure, but the filing still leaves him with 154,502 shares after the sale.

The Rule 10b5-1 language is the strongest caveat. It means the sale can reflect a schedule set in advance, and the filing ties the trade to that plan. On that reading, the trade is more a record of timing than of conviction. It is a preset sale signal, not a new operating claim.

What's next

What's next is the next quarterly report, the next scheduled check on the company's operating story. If it shows continued progress in orders, reimbursement and scale and cash generation, the insider sale will look routine. If it does not, this filing will matter more because it showed the CEO trimming while the thesis was still untested. That will be the next real test.